Leukemia Clinical Trials 2026: AML, CLL, ALL and New Treatments

Leukemia research encompasses four major disease categories — AML, ALL, CLL, and CML — each with its own biology, treatment history, and trial landscape. CML became a model for targeted therapy in oncology when imatinib achieved durable remission in what was once a uniformly fatal disease; the question three decades later is whether that model can be replicated in the more genetically complex AMLs. The ALL story in 2026 is being written by pediatric oncology's success rates and the challenge of extending those rates to adult patients, where outcomes remain substantially worse.

Acute Myeloid Leukemia (AML) Trials 2026

AML is the most common acute leukemia in adults, with median age at diagnosis of 68. Historically, outcomes were poor for older patients ineligible for intensive chemotherapy — but the venetoclax (Venclexta) + azacitidine combination changed the standard of care in 2020. 2026 trials are pushing further:

Menin Inhibitors: The New Targeted Therapy

Revumenib (Revuforj) — FDA-approved November 2023 — is the first drug specifically approved for KMT2A-rearranged AML. Ziftomenib is now in Phase 3 (KOMET-008) for NPM1-mutant AML. Current trials are testing menin inhibitors earlier: combined with venetoclax+azacitidine in newly diagnosed KMT2A/NPM1-mutant patients, and as maintenance post-transplant. These trials represent the highest-priority access pathway for patients with these genetic markers.

FLT3-Mutant AML: Beyond Midostaurin

FLT3 mutations occur in ~30% of AML patients. Gilteritinib (Xospata) is standard second-line therapy. 2026 trials: quizartinib + venetoclax + azacitidine (QuAVA) for newly diagnosed FLT3-mutant AML; FLT3 CAR-T Phase 1; bispecific antibodies targeting FLT3. The LACEWING trial tested gilteritinib maintenance post-transplant — results now informing maintenance protocols.

Venetoclax Combinations and Resistance

Venetoclax resistance is emerging as the central AML research problem. Trials studying: magrolimab (anti-CD47) + venetoclax for TP53-mutant AML; ivosidenib + venetoclax for IDH1-mutant disease; navitoclax overcoming BCL-XL-mediated resistance; and triplet regimens adding targeted agents to the Ven+Aza backbone. Most trials require prior venetoclax exposure or venetoclax-naive newly diagnosed patients — not both.

Chronic Lymphocytic Leukemia (CLL) Trials 2026

CLL has been transformed by BTK inhibitors (ibrutinib, acalabrutinib, zanubrutinib) and venetoclax. In 2026, the focus is on: fixed-duration combinations to achieve treatment-free remission, and new agents for BTK-inhibitor resistant disease.

Pirtobrutinib for BTK-Mutant Relapsed CLL

Pirtobrutinib (Jaypirca) is a non-covalent BTK inhibitor that retains activity against the C481S BTK mutation responsible for most covalent BTK inhibitor resistance. FDA-approved in 2023, BRUIN-CLL-321 Phase 3 trial confirmed superiority over investigator's choice in post-BTKi/venetoclax CLL. 2026 trials are moving pirtobrutinib earlier and testing combinations with venetoclax.

Fixed-Duration Combinations for Treatment-Free Remission

The CLL14 trial established fixed-duration venetoclax+obinutuzumab. 2026 trials are testing: zanubrutinib+venetoclax (SEQUOIA, BGB-3111-304), acalabrutinib+venetoclax+obinutuzumab (ACE-CLL-311), and ibrutinib+venetoclax (GLOW, CAPTIVATE). Goal: achieve undetectable minimal residual disease (MRD-neg) and stop therapy, reserving re-treatment for relapse. Key eligibility: 17p deletion, IGHV mutation status, and treatment history determine which regimen is most relevant.

Acute Lymphoblastic Leukemia (ALL) Trials 2026

Adult ALL is rare but aggressive. Blinatumomab (Blincyto) has now moved from relapsed/refractory into frontline consolidation after the E1910 trial showed survival benefit in MRD-positive Ph-negative ALL. CAR-T is expanding for adult relapsed/refractory ALL.

CAR-T Trials for Relapsed/Refractory ALL

Tisagenlecleucel (Kymriah) remains the only CD19 CAR-T approved for adult ALL (up to age 25). Trials in 2026 include: axicabtagene ciloleucel for adult ALL (previously only studied in DLBCL); CD22-directed CAR-T for CD19-loss relapses after prior CD19 CAR-T; and dual CD19/CD22 CAR-T to prevent antigen escape. Key eligibility: relapsed or refractory after 2 prior lines, adequate organ function, no prior CAR-T (most trials).

How to Access Leukemia Trials

Molecular profiling is essential

Most modern leukemia trials require specific genetic mutations (FLT3, IDH1/IDH2, KMT2A, NPM1, TP53, IGHV). Comprehensive genomic testing (NGS panel) at diagnosis or relapse is the first step — without it, you cannot identify eligible targeted therapy trials.

Academic hematology centers

Leukemia trials are concentrated at NCI-designated Cancer Centers (US), INCA-affiliated centers (France), NHS Comprehensive Cancer Centres (UK), and university hospital hematology departments (Germany, Netherlands). Community oncologists typically refer eligible patients to trial sites.

Timing matters

AML trials often have narrow enrollment windows — at diagnosis (frontline trials) or at first relapse (salvage trials). Patients with rapidly progressing disease may not have time to travel to distant trial sites. Discussing trial options before relapse — while in remission — allows for better planning.